AB0008 Type I Interferon Gene Response is Associated with Early Rheumatoid Arthritis (RA)

BackgroundRheumatoid arthritis (RA) is often accompanied by severe inflammation joint destruction and circulating autoantibodies. Recently it as been described that inflammatory responses associated with type I interferon are associated with the disease, however, there is no information regarding th...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of the rheumatic diseases 2015-06, Vol.74 (Suppl 2), p.893
Hauptverfasser: Enciso-Moreno, J.A., Castañeda-Delgado, J.E., Macias-Segura, N., Santiago-Algarra, D., Castillo-Ortiz, J.D., Alemán-Navarro, A.L., Martínez-Tejada, P., García-De Lira, Y., Olgín-Calderόn, D., Enciso-Moreno, L., Bastián-Hernández, Y., Ramos-Remus, C.R.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue Suppl 2
container_start_page 893
container_title Annals of the rheumatic diseases
container_volume 74
creator Enciso-Moreno, J.A.
Castañeda-Delgado, J.E.
Macias-Segura, N.
Santiago-Algarra, D.
Castillo-Ortiz, J.D.
Alemán-Navarro, A.L.
Martínez-Tejada, P.
García-De Lira, Y.
Olgín-Calderόn, D.
Enciso-Moreno, L.
Bastián-Hernández, Y.
Ramos-Remus, C.R.
description BackgroundRheumatoid arthritis (RA) is often accompanied by severe inflammation joint destruction and circulating autoantibodies. Recently it as been described that inflammatory responses associated with type I interferon are associated with the disease, however, there is no information regarding the role of the response of these associated gene signatures with other stages of the disease such as early RA or individuals at risk such as those with anticitrullinated antibodies and direct and family history of RA.ObjectivesTo evaluate the relative gene expression of the genes IFI44L, IFI6, IFIT1, IFIT2, IFI35, ISG15, MXB, MXA, Ly6E, RSAD2, HERC5, EPSTRI1 in blood samples isolated from patients with RA and their family members with preclinical stages of the disease.MethodsBlood samples from Mexican patients with early RA (eRA; n=10) and patients with chronic RA with more than 2 years with the disease (cRA; n=20) were collected. All cRA patients had received treatment with DMARD's. First-degree relatives of patients with RA were stratified in positive (ACCP+; n=20) or negative (ACCP-; n=20) to ACCP. Subjects without family history of autoimmune diseases were included in a healthy control group (HC; n=20). Serum levels of ACCP were evaluated using second generation ELISA. RNA was isolated and integrity was verified in a Bioanalyzer (Life Technologies), only samples with RIN scores>6 were used for cDNA synthesis by a superscript II reverse transcription system (Invitrogen), according to manufacturers instructions.qPCR analysis of the samples was carried out in a Lightcycler 480 (Roche diagnostics) and normalized using HPRT. Statistical analysis for group comparison was done using the Kruskal-Wallis test for non-parametric data, with p
doi_str_mv 10.1136/annrheumdis-2015-eular.5358
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1901789677</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4322504023</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1277-dadea0b4e09a0066b47c49344d0804808305ac8208e477164ae6ddc8c7b41373</originalsourceid><addsrcrecordid>eNqVkLtOwzAUhi0EEqXwDpa6wJBy3Di2I6ZQlVKpElLVjcFy4lM1VesEOxHqxsKL8iQklIGV6Vz0_-fyETJiMGYsFvfGOb_F9mDLEE2AJRG2e-PHSZyoMzJgXKiuLeCcDAAgjngq5CW5CmHXlaCYGpDX7LFPvz4-18ca6YIuXIN-g75ydI4O6QpDXbmAtAw0C6EqStOgpe9ls6Uz4_dHuuovME1VWpr5ZuvLppPerrK7a3KxMfuAN79xSNZPs_X0OVq-zBfTbBnlbCJlZI1FAzlHSA2AEDmXBU9jzi0o4ApUDIkp1AQUcimZ4AaFtYUqZM5ZLOMhGZ3G1r56azE0ele13nUbNUuBSdV93aseTqrCVyF43Ojalwfjj5qB7mHqPzB1D1P_wNQ9zM4tTu78sPuX8RvxYX9V</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1901789677</pqid></control><display><type>article</type><title>AB0008 Type I Interferon Gene Response is Associated with Early Rheumatoid Arthritis (RA)</title><source>BMJ Journals - NESLi2</source><creator>Enciso-Moreno, J.A. ; Castañeda-Delgado, J.E. ; Macias-Segura, N. ; Santiago-Algarra, D. ; Castillo-Ortiz, J.D. ; Alemán-Navarro, A.L. ; Martínez-Tejada, P. ; García-De Lira, Y. ; Olgín-Calderόn, D. ; Enciso-Moreno, L. ; Bastián-Hernández, Y. ; Ramos-Remus, C.R.</creator><creatorcontrib>Enciso-Moreno, J.A. ; Castañeda-Delgado, J.E. ; Macias-Segura, N. ; Santiago-Algarra, D. ; Castillo-Ortiz, J.D. ; Alemán-Navarro, A.L. ; Martínez-Tejada, P. ; García-De Lira, Y. ; Olgín-Calderόn, D. ; Enciso-Moreno, L. ; Bastián-Hernández, Y. ; Ramos-Remus, C.R.</creatorcontrib><description>BackgroundRheumatoid arthritis (RA) is often accompanied by severe inflammation joint destruction and circulating autoantibodies. Recently it as been described that inflammatory responses associated with type I interferon are associated with the disease, however, there is no information regarding the role of the response of these associated gene signatures with other stages of the disease such as early RA or individuals at risk such as those with anticitrullinated antibodies and direct and family history of RA.ObjectivesTo evaluate the relative gene expression of the genes IFI44L, IFI6, IFIT1, IFIT2, IFI35, ISG15, MXB, MXA, Ly6E, RSAD2, HERC5, EPSTRI1 in blood samples isolated from patients with RA and their family members with preclinical stages of the disease.MethodsBlood samples from Mexican patients with early RA (eRA; n=10) and patients with chronic RA with more than 2 years with the disease (cRA; n=20) were collected. All cRA patients had received treatment with DMARD's. First-degree relatives of patients with RA were stratified in positive (ACCP+; n=20) or negative (ACCP-; n=20) to ACCP. Subjects without family history of autoimmune diseases were included in a healthy control group (HC; n=20). Serum levels of ACCP were evaluated using second generation ELISA. RNA was isolated and integrity was verified in a Bioanalyzer (Life Technologies), only samples with RIN scores&gt;6 were used for cDNA synthesis by a superscript II reverse transcription system (Invitrogen), according to manufacturers instructions.qPCR analysis of the samples was carried out in a Lightcycler 480 (Roche diagnostics) and normalized using HPRT. Statistical analysis for group comparison was done using the Kruskal-Wallis test for non-parametric data, with p&lt;0.05 considered significant. A spearman correlation was also performed.ResultsNo differences were found for clinically relevant variables (HC, ACCP-, ACCP+, eRA and cRA). Differences between the chronic arthritis group and the healthy controls were identified for IFIT1, IFIT2, IFI35, ISG15, Ly6E, HERC5, RSAD2, EPSTRI1 and MXA (p&lt;0.05) confirming previous reports in our population. However, differences among the healthy controls or the ACPA- individuals and the eRA cases were also identified for the genes IFI 5, MXA and MXB (P&lt;0.05). A significant correlation was found for several genes in the signalling cascade such as IFIT1, EPSTRI1, IFI35, LY6E, HERC5 and MXA (P&lt;0.05) suggesting that once that the cascade has been initiated, al genes belonging to the cascade are expressed to regulate the type I interferon gene response.ConclusionsThe gene expression signature of the type IFN response is overexpressed in the majority of the genes analysed, however, several of these genes are also overexpressed in the early RA subjects, suggesting that the expression of these genes might be used as an early detection system for patients with early disease symptoms. The use of the markers to further advance the classification of undifferentiated arthralgia and early RA needs to be further explored.Disclosure of InterestNone declared</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/annrheumdis-2015-eular.5358</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>Kidlington: Elsevier Limited</publisher><ispartof>Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.893</ispartof><rights>2015, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2015 (c) 2015, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttp://ard.bmj.com/content/74/Suppl_2/893.3.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttp://ard.bmj.com/content/74/Suppl_2/893.3.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,314,776,780,3183,23550,27901,27902,77342,77373</link.rule.ids></links><search><creatorcontrib>Enciso-Moreno, J.A.</creatorcontrib><creatorcontrib>Castañeda-Delgado, J.E.</creatorcontrib><creatorcontrib>Macias-Segura, N.</creatorcontrib><creatorcontrib>Santiago-Algarra, D.</creatorcontrib><creatorcontrib>Castillo-Ortiz, J.D.</creatorcontrib><creatorcontrib>Alemán-Navarro, A.L.</creatorcontrib><creatorcontrib>Martínez-Tejada, P.</creatorcontrib><creatorcontrib>García-De Lira, Y.</creatorcontrib><creatorcontrib>Olgín-Calderόn, D.</creatorcontrib><creatorcontrib>Enciso-Moreno, L.</creatorcontrib><creatorcontrib>Bastián-Hernández, Y.</creatorcontrib><creatorcontrib>Ramos-Remus, C.R.</creatorcontrib><title>AB0008 Type I Interferon Gene Response is Associated with Early Rheumatoid Arthritis (RA)</title><title>Annals of the rheumatic diseases</title><description>BackgroundRheumatoid arthritis (RA) is often accompanied by severe inflammation joint destruction and circulating autoantibodies. Recently it as been described that inflammatory responses associated with type I interferon are associated with the disease, however, there is no information regarding the role of the response of these associated gene signatures with other stages of the disease such as early RA or individuals at risk such as those with anticitrullinated antibodies and direct and family history of RA.ObjectivesTo evaluate the relative gene expression of the genes IFI44L, IFI6, IFIT1, IFIT2, IFI35, ISG15, MXB, MXA, Ly6E, RSAD2, HERC5, EPSTRI1 in blood samples isolated from patients with RA and their family members with preclinical stages of the disease.MethodsBlood samples from Mexican patients with early RA (eRA; n=10) and patients with chronic RA with more than 2 years with the disease (cRA; n=20) were collected. All cRA patients had received treatment with DMARD's. First-degree relatives of patients with RA were stratified in positive (ACCP+; n=20) or negative (ACCP-; n=20) to ACCP. Subjects without family history of autoimmune diseases were included in a healthy control group (HC; n=20). Serum levels of ACCP were evaluated using second generation ELISA. RNA was isolated and integrity was verified in a Bioanalyzer (Life Technologies), only samples with RIN scores&gt;6 were used for cDNA synthesis by a superscript II reverse transcription system (Invitrogen), according to manufacturers instructions.qPCR analysis of the samples was carried out in a Lightcycler 480 (Roche diagnostics) and normalized using HPRT. Statistical analysis for group comparison was done using the Kruskal-Wallis test for non-parametric data, with p&lt;0.05 considered significant. A spearman correlation was also performed.ResultsNo differences were found for clinically relevant variables (HC, ACCP-, ACCP+, eRA and cRA). Differences between the chronic arthritis group and the healthy controls were identified for IFIT1, IFIT2, IFI35, ISG15, Ly6E, HERC5, RSAD2, EPSTRI1 and MXA (p&lt;0.05) confirming previous reports in our population. However, differences among the healthy controls or the ACPA- individuals and the eRA cases were also identified for the genes IFI 5, MXA and MXB (P&lt;0.05). A significant correlation was found for several genes in the signalling cascade such as IFIT1, EPSTRI1, IFI35, LY6E, HERC5 and MXA (P&lt;0.05) suggesting that once that the cascade has been initiated, al genes belonging to the cascade are expressed to regulate the type I interferon gene response.ConclusionsThe gene expression signature of the type IFN response is overexpressed in the majority of the genes analysed, however, several of these genes are also overexpressed in the early RA subjects, suggesting that the expression of these genes might be used as an early detection system for patients with early disease symptoms. The use of the markers to further advance the classification of undifferentiated arthralgia and early RA needs to be further explored.Disclosure of InterestNone declared</description><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNqVkLtOwzAUhi0EEqXwDpa6wJBy3Di2I6ZQlVKpElLVjcFy4lM1VesEOxHqxsKL8iQklIGV6Vz0_-fyETJiMGYsFvfGOb_F9mDLEE2AJRG2e-PHSZyoMzJgXKiuLeCcDAAgjngq5CW5CmHXlaCYGpDX7LFPvz4-18ca6YIuXIN-g75ydI4O6QpDXbmAtAw0C6EqStOgpe9ls6Uz4_dHuuovME1VWpr5ZuvLppPerrK7a3KxMfuAN79xSNZPs_X0OVq-zBfTbBnlbCJlZI1FAzlHSA2AEDmXBU9jzi0o4ApUDIkp1AQUcimZ4AaFtYUqZM5ZLOMhGZ3G1r56azE0ele13nUbNUuBSdV93aseTqrCVyF43Ojalwfjj5qB7mHqPzB1D1P_wNQ9zM4tTu78sPuX8RvxYX9V</recordid><startdate>201506</startdate><enddate>201506</enddate><creator>Enciso-Moreno, J.A.</creator><creator>Castañeda-Delgado, J.E.</creator><creator>Macias-Segura, N.</creator><creator>Santiago-Algarra, D.</creator><creator>Castillo-Ortiz, J.D.</creator><creator>Alemán-Navarro, A.L.</creator><creator>Martínez-Tejada, P.</creator><creator>García-De Lira, Y.</creator><creator>Olgín-Calderόn, D.</creator><creator>Enciso-Moreno, L.</creator><creator>Bastián-Hernández, Y.</creator><creator>Ramos-Remus, C.R.</creator><general>Elsevier Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope></search><sort><creationdate>201506</creationdate><title>AB0008 Type I Interferon Gene Response is Associated with Early Rheumatoid Arthritis (RA)</title><author>Enciso-Moreno, J.A. ; Castañeda-Delgado, J.E. ; Macias-Segura, N. ; Santiago-Algarra, D. ; Castillo-Ortiz, J.D. ; Alemán-Navarro, A.L. ; Martínez-Tejada, P. ; García-De Lira, Y. ; Olgín-Calderόn, D. ; Enciso-Moreno, L. ; Bastián-Hernández, Y. ; Ramos-Remus, C.R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1277-dadea0b4e09a0066b47c49344d0804808305ac8208e477164ae6ddc8c7b41373</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Enciso-Moreno, J.A.</creatorcontrib><creatorcontrib>Castañeda-Delgado, J.E.</creatorcontrib><creatorcontrib>Macias-Segura, N.</creatorcontrib><creatorcontrib>Santiago-Algarra, D.</creatorcontrib><creatorcontrib>Castillo-Ortiz, J.D.</creatorcontrib><creatorcontrib>Alemán-Navarro, A.L.</creatorcontrib><creatorcontrib>Martínez-Tejada, P.</creatorcontrib><creatorcontrib>García-De Lira, Y.</creatorcontrib><creatorcontrib>Olgín-Calderόn, D.</creatorcontrib><creatorcontrib>Enciso-Moreno, L.</creatorcontrib><creatorcontrib>Bastián-Hernández, Y.</creatorcontrib><creatorcontrib>Ramos-Remus, C.R.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Enciso-Moreno, J.A.</au><au>Castañeda-Delgado, J.E.</au><au>Macias-Segura, N.</au><au>Santiago-Algarra, D.</au><au>Castillo-Ortiz, J.D.</au><au>Alemán-Navarro, A.L.</au><au>Martínez-Tejada, P.</au><au>García-De Lira, Y.</au><au>Olgín-Calderόn, D.</au><au>Enciso-Moreno, L.</au><au>Bastián-Hernández, Y.</au><au>Ramos-Remus, C.R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>AB0008 Type I Interferon Gene Response is Associated with Early Rheumatoid Arthritis (RA)</atitle><jtitle>Annals of the rheumatic diseases</jtitle><date>2015-06</date><risdate>2015</risdate><volume>74</volume><issue>Suppl 2</issue><spage>893</spage><pages>893-</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>BackgroundRheumatoid arthritis (RA) is often accompanied by severe inflammation joint destruction and circulating autoantibodies. Recently it as been described that inflammatory responses associated with type I interferon are associated with the disease, however, there is no information regarding the role of the response of these associated gene signatures with other stages of the disease such as early RA or individuals at risk such as those with anticitrullinated antibodies and direct and family history of RA.ObjectivesTo evaluate the relative gene expression of the genes IFI44L, IFI6, IFIT1, IFIT2, IFI35, ISG15, MXB, MXA, Ly6E, RSAD2, HERC5, EPSTRI1 in blood samples isolated from patients with RA and their family members with preclinical stages of the disease.MethodsBlood samples from Mexican patients with early RA (eRA; n=10) and patients with chronic RA with more than 2 years with the disease (cRA; n=20) were collected. All cRA patients had received treatment with DMARD's. First-degree relatives of patients with RA were stratified in positive (ACCP+; n=20) or negative (ACCP-; n=20) to ACCP. Subjects without family history of autoimmune diseases were included in a healthy control group (HC; n=20). Serum levels of ACCP were evaluated using second generation ELISA. RNA was isolated and integrity was verified in a Bioanalyzer (Life Technologies), only samples with RIN scores&gt;6 were used for cDNA synthesis by a superscript II reverse transcription system (Invitrogen), according to manufacturers instructions.qPCR analysis of the samples was carried out in a Lightcycler 480 (Roche diagnostics) and normalized using HPRT. Statistical analysis for group comparison was done using the Kruskal-Wallis test for non-parametric data, with p&lt;0.05 considered significant. A spearman correlation was also performed.ResultsNo differences were found for clinically relevant variables (HC, ACCP-, ACCP+, eRA and cRA). Differences between the chronic arthritis group and the healthy controls were identified for IFIT1, IFIT2, IFI35, ISG15, Ly6E, HERC5, RSAD2, EPSTRI1 and MXA (p&lt;0.05) confirming previous reports in our population. However, differences among the healthy controls or the ACPA- individuals and the eRA cases were also identified for the genes IFI 5, MXA and MXB (P&lt;0.05). A significant correlation was found for several genes in the signalling cascade such as IFIT1, EPSTRI1, IFI35, LY6E, HERC5 and MXA (P&lt;0.05) suggesting that once that the cascade has been initiated, al genes belonging to the cascade are expressed to regulate the type I interferon gene response.ConclusionsThe gene expression signature of the type IFN response is overexpressed in the majority of the genes analysed, however, several of these genes are also overexpressed in the early RA subjects, suggesting that the expression of these genes might be used as an early detection system for patients with early disease symptoms. The use of the markers to further advance the classification of undifferentiated arthralgia and early RA needs to be further explored.Disclosure of InterestNone declared</abstract><cop>Kidlington</cop><pub>Elsevier Limited</pub><doi>10.1136/annrheumdis-2015-eular.5358</doi></addata></record>
fulltext fulltext
identifier ISSN: 0003-4967
ispartof Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.893
issn 0003-4967
1468-2060
language eng
recordid cdi_proquest_journals_1901789677
source BMJ Journals - NESLi2
title AB0008 Type I Interferon Gene Response is Associated with Early Rheumatoid Arthritis (RA)
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T04%3A19%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=AB0008%E2%80%85Type%20I%20Interferon%20Gene%20Response%20is%20Associated%20with%20Early%20Rheumatoid%20Arthritis%20(RA)&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Enciso-Moreno,%20J.A.&rft.date=2015-06&rft.volume=74&rft.issue=Suppl%202&rft.spage=893&rft.pages=893-&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/annrheumdis-2015-eular.5358&rft_dat=%3Cproquest_cross%3E4322504023%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1901789677&rft_id=info:pmid/&rfr_iscdi=true